Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  sargramostim
Find trials that include:  Any drugs shown
Results 1-25 of 27 for your search:
Start Over
Nivolumab and Ipilimumab with or without Sargramostim in Treating Patients with Stage III-IV Melanoma That Cannot Be Removed by Surgery
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EA6141, NCI-2014-02674, NCT02339571
Isotretinoin with or without Dinutuximab, Aldesleukin, and Sargramostim following Stem Cell Transplant in Treating Patients with Neuroblastoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 30 and under at diagnosis
Trial IDs: ANBL0032, NCI-2009-01064, CDR0000069018, COG-ANBL0032, COG-P9842, NCT00026312
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CL-CA-P01, NCI-2015-00099, 2014-000544-15, 2015-001984-38, CL-CA-P01-00-US, NCT01875653
Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: STML-701-0114, NCI-2014-01008, NCT02078648
OKT3/Humanized 3F8 Bispecific Antibody-Activated T Lymphocytes, Aldesleukin, and Sargramostim in Treating Younger Patients with GD2-Positive Metastatic, Recurrent or Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 13 moths to 29 years
Trial IDs: 2013-171, NCI-2014-01149, 1403012875, NCT02173093
Recombinant Interferon Alpha-2a and Sargramostim or Vaccine Therapy in Treating Patients with Chronic Phase Chronic Myelogenous Leukemia Receiving Tyrosine Kinase Inhibitor Therapy
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: J05121, NCI-2011-00392, CDR0000492005, JHOC-J05121, NA_00001887, NCT00363649
Vaccine Therapy, Trastuzumab, and Vinorelbine Tartrate in Treating Patients With Metastatic Breast Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LCCC 0418, NCI-2013-00498, UNC-LCCC-0418, NCT00266110
Vaccine Therapy in Treating Patients with Malignant Mesothelioma Previously Treated with Combined Modality Therapy
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-134, NCI-2010-02375, NCT01265433
Phase II Ofatumumab/Methylprednisolone Followed by Ofatumumab/Lenalidomide for Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MCC-16622, NCI-2012-00066, GSK OFT114879, RV-CLL-PI-0560, NCT01496976
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 368255, NCI-2015-00026, 1137008 / 20130058, NCT01570036
Sipuleucel-T with or without DNA Vaccine Therapy in Treating Patients with Hormone-Resistant Metastatic Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CO11816, NCI-2012-02026, NCT01706458
Irinotecan Hydrochloride and Temozolomide with Temsirolimus or Monoclonal Antibody Ch14.18 in Treating Younger Patients with Refractory or Relapsed Neuroblastoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Children
Trial IDs: ANBL1221, NCI-2012-03125, CDR0000745188, COG-ANBL1221, NCT01767194
ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: ERC1671-H02, NCI-2014-00737, 2013-9863, ERC1671, UCI 13-14, NCT01903330
Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0443, NCI-2015-00033, NCT02297698
SurVaxM Vaccine Therapy and Temozolomide in Treating Patients with Newly Diagnosed Glioblastoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 259614, NCI-2015-00694, NCT02455557
Monoclonal Antibody 3F8 and Sargramostim in Treating Patients with Relapsed or Refractory High-Risk Neuroblastoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 1
Trial IDs: 12-230, NCI-2013-00007, NCT01757626
Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBMPI03-Hem-01, NCI-2015-00929, NCT02240537
Filgrastim-Stimulated Bone Marrow Transplant in Treating Patients with Hematological Malignancies without Matched Donors
Phase: No phase specified
Type: Treatment
Age: Under 22
Trial IDs: 21819, NCI-2014-01418, 0159-2004, 159-2004 (G-CSF PMRD Feasibility), CR6_IRB00021819, EMORY IRB # 21819, G-CSF PMRD, NCT00228813
Peripheral Blood Stem Cell Transplant in Treating Patients with Acute Myeloid Leukemia
Phase: No phase specified
Type: Treatment
Age: 70 and under
Trial IDs: MT2006-13, NCI-2010-02369, 0607M89052, UMN-MT2006-13, NCT00630565
Vaccine Therapy in Treating Patients with Multiple Myeloma Who Have Undergone Stem Cell Transplant
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-288, NCI-2013-00802, NCT01827137
Monoclonal Antibody 3F8 and Sargramostim in Treating Patients with High-Risk Neuroblastoma
Phase: No phase specified
Type: Treatment
Age: Not specified
Trial IDs: 13-260, NCI-2014-00815, NCT02100930
Start Over